Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 282 entries
Sorted by: Best Match Show Resources per page
Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals.

GMS ophthalmology cases

Prud'homme S, Nevens F, Casteels I.
PMID: 27625964
GMS Ophthalmol Cases. 2016 Apr 04;6:Doc05. doi: 10.3205/oc000042. eCollection 2016.

We report a patient with a bilateral optic anterior ischemic neuropathy as an extrahepatic complication of a chronic hepatitis C (HCV) infection. The patient presented with a bilateral visual acuity loss and bilateral optic disc oedema. The optic neuropathy...

Cite
Prud'homme S, Nevens F, Casteels I. Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases. 2016;6:Doc05doi: 10.3205/oc000042.
Prud'homme, S., Nevens, F., & Casteels, I. (2016). Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS ophthalmology cases, 6Doc05. https://doi.org/10.3205/oc000042
Prud'homme, Sylvie, et al. "Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals." GMS ophthalmology cases vol. 6 (2016): Doc05. doi: https://doi.org/10.3205/oc000042
Prud'homme S, Nevens F, Casteels I. Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases. 2016 Apr 04;6:Doc05. doi: 10.3205/oc000042. eCollection 2016. PMID: 27625964; PMCID: PMC5015795.
Copy Download .nbib Format: NLM
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).

Antiviral therapy

Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M.
PMID: 26313445
Antivir Ther. 2015 Aug 27;21(3):195-205. doi: 10.3851/IMP2985. Epub 2015 Aug 27.

BACKGROUND: Treatment options for HCV genotype-4 (GT4) are limited. This Phase III study (COMMAND-4; AI444-042) evaluated the efficacy and safety of daclatasvir (DCV), a pan-genotypic HCV NS5A inhibitor, with pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in treatment-naive patients with HCV GT4 infection.METHODS:...

Cite
Hézode C, Alric L, Brown A, et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015;21(3):195-205doi: 10.3851/IMP2985.
Hézode, C., Alric, L., Brown, A., Hassanein, T., Rizzetto, M., Buti, M., Bourlière, M., Thabut, D., Molina, E., Rustgi, V., Samuel, D., McPhee, F., Liu, Z., Yin, P. D., Hughes, E., Treitel, M. (2015). Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antiviral therapy, 21(3), 195-205. https://doi.org/10.3851/IMP2985
Hézode, Christophe, et al. "Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)." Antiviral therapy vol. 21,3 (2015): 195-205. doi: https://doi.org/10.3851/IMP2985
Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015 Aug 27;21(3):195-205. doi: 10.3851/IMP2985. Epub 2015 Aug 27. PMID: 26313445.
Copy Download .nbib Format: NLM
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.

Clinical case reports

Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES.
PMID: 28396749
Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr.

This case suggests that initiation of HCV therapy immediately after liver transplantation with well-tolerated, all-oral regimens may achieve a virologic cure in HCV-positive recipients, thus preventing post-transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of...

Cite
Poordad F, Lawitz E, Gutierrez JA, et al. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017;5(4):371-375doi: 10.1002/ccr3.841.
Poordad, F., Lawitz, E., Gutierrez, J. A., Guerrero, J., Speeg, K., & Swenson, E. S. (2017). An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clinical case reports, 5(4), 371-375. https://doi.org/10.1002/ccr3.841
Poordad, Fred, et al. "An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin." Clinical case reports vol. 5,4 (2017): 371-375. doi: https://doi.org/10.1002/ccr3.841
Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr. PMID: 28396749; PMCID: PMC5378822.
Copy Download .nbib Format: NLM
Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.

Current infectious disease reports

Johnson SW, Thompson DK, Raccor B.
PMID: 28421422
Curr Infect Dis Rep. 2017 Jun;19(6):22. doi: 10.1007/s11908-017-0578-5.

PURPOSE OF REVIEW: Direct-acting antiviral agents (DAAs) have markedly improved the prognosis of hepatitis C virus (HCV)-genotype 3 (GT3), a highly prevalent infection worldwide. However, in patients with hepatic fibrosis, cirrhosis, or hepatocellular carcinoma (HCC), GT3 infection presents a...

Cite
Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep. 2017;19(6):22doi: 10.1007/s11908-017-0578-5.
Johnson, S. W., Thompson, D. K., & Raccor, B. (2017). Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Current infectious disease reports, 19(6), 22. https://doi.org/10.1007/s11908-017-0578-5
Johnson, Steven W, et al. "Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions." Current infectious disease reports vol. 19,6 (2017): 22. doi: https://doi.org/10.1007/s11908-017-0578-5
Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep. 2017 Jun;19(6):22. doi: 10.1007/s11908-017-0578-5. PMID: 28421422.
Copy Download .nbib Format: NLM
Hepatitis C genotype 4: The past, present, and future.

World journal of hepatology

Abdel-Ghaffar TY, Sira MM, El Naghi S.
PMID: 26668691
World J Hepatol. 2015 Dec 08;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792.

Hepatitis C virus (HCV) genotype (GT) 4 represents 12%-15% (15-18 million) of total global HCV infection. It is prevalent in Northern and Equatorial Africa and the Middle East, and is also present in some countries in Europe. GT-4 (and...

Cite
Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol. 2015;7(28):2792-810doi: 10.4254/wjh.v7.i28.2792.
Abdel-Ghaffar, T. Y., Sira, M. M., & El Naghi, S. (2015). Hepatitis C genotype 4: The past, present, and future. World journal of hepatology, 7(28), 2792-810. https://doi.org/10.4254/wjh.v7.i28.2792
Abdel-Ghaffar, Tawhida Y, et al. "Hepatitis C genotype 4: The past, present, and future." World journal of hepatology vol. 7,28 (2015): 2792-810. doi: https://doi.org/10.4254/wjh.v7.i28.2792
Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol. 2015 Dec 08;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792. PMID: 26668691; PMCID: PMC4670951.
Copy Download .nbib Format: NLM
Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease.

Hepatology research : the official journal of the Japan Society of Hepatology

Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Asano T, Yoshizawa K, Okubo T, Chuganji Y, Aizawa Y, Iio E, Tanaka Y, Iwakiri K.
PMID: 28225572
Hepatol Res. 2017 Oct;47(11):1165-1173. doi: 10.1111/hepr.12879. Epub 2017 Apr 12.

AIM: To evaluate the efficacy and safety of daclatasvir and asunaprevir combined therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD).METHODS: In a multicenter collaborative study, 249 patients received 60 mg daclatasvir (NS5A inhibitor)...

Cite
Kondo C, Atsukawa M, Tsubota A, et al. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res. 2017;47(11):1165-1173doi: 10.1111/hepr.12879.
Kondo, C., Atsukawa, M., Tsubota, A., Shimada, N., Abe, H., Asano, T., Yoshizawa, K., Okubo, T., Chuganji, Y., Aizawa, Y., Iio, E., Tanaka, Y., & Iwakiri, K. (2017). Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatology research : the official journal of the Japan Society of Hepatology, 47(11), 1165-1173. https://doi.org/10.1111/hepr.12879
Kondo, Chisa, et al. "Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,11 (2017): 1165-1173. doi: https://doi.org/10.1111/hepr.12879
Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Asano T, Yoshizawa K, Okubo T, Chuganji Y, Aizawa Y, Iio E, Tanaka Y, Iwakiri K. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res. 2017 Oct;47(11):1165-1173. doi: 10.1111/hepr.12879. Epub 2017 Apr 12. PMID: 28225572.
Copy Download .nbib Format: NLM
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Cl.

Gastroenterology & hepatology

[No authors listed]
PMID: 26504459
Gastroenterol Hepatol (N Y). 2015 Jun;11(6):1-23.

No abstract available.

Cite
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Cl. Gastroenterol Hepatol (N Y). 2015;11(6):1-23
(2015). A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Cl. Gastroenterology & hepatology, 11(6), 1-23.
"A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Cl." Gastroenterology & hepatology vol. 11,6 (2015): 1-23.
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Cl. Gastroenterol Hepatol (N Y). 2015 Jun;11(6):1-23. PMID: 26504459; PMCID: PMC4617178.
Copy Download .nbib Format: NLM
Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir.

World journal of clinical cases

Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, Kusano M, Yamada M.
PMID: 26677451
World J Clin Cases. 2015 Dec 16;3(12):1005-10. doi: 10.12998/wjcc.v3.i12.1005.

A 66-year-old, interferon-ineligible, treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C virus genotype 1b began combination therapy with daclatasvir and asunaprevir. On day 14 of treatment, hepatic reserve and renal function deterioration was observed,...

Cite
Suga T, Sato K, Yamazaki Y, et al. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases. 2015;3(12):1005-10doi: 10.12998/wjcc.v3.i12.1005.
Suga, T., Sato, K., Yamazaki, Y., Ohyama, T., Horiguchi, N., Kakizaki, S., Kusano, M., & Yamada, M. (2015). Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World journal of clinical cases, 3(12), 1005-10. https://doi.org/10.12998/wjcc.v3.i12.1005
Suga, Takayoshi, et al. "Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir." World journal of clinical cases vol. 3,12 (2015): 1005-10. doi: https://doi.org/10.12998/wjcc.v3.i12.1005
Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases. 2015 Dec 16;3(12):1005-10. doi: 10.12998/wjcc.v3.i12.1005. PMID: 26677451; PMCID: PMC4677081.
Copy Download .nbib Format: NLM
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.

Open forum infectious diseases

Martinello M, Dore GJ, Skurowski J, Bopage RI, Finlayson R, Baker D, Bloch M, Matthews GV.
PMID: 27419177
Open Forum Infect Dis. 2016 May 18;3(2):ofw105. doi: 10.1093/ofid/ofw105. eCollection 2016 Apr.

Background.  Interferon-free direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) provide a major advance in clinical management, including in human immunodeficiency virus (HIV)/HCV coinfection. Drug-drug interactions (DDIs) with combination antiretroviral therapy (cART) require consideration. This study aimed to...

Cite
Martinello M, Dore GJ, Skurowski J, et al. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infect Dis. 2016;3(2):ofw105doi: 10.1093/ofid/ofw105.
Martinello, M., Dore, G. J., Skurowski, J., Bopage, R. I., Finlayson, R., Baker, D., Bloch, M., & Matthews, G. V. (2016). Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open forum infectious diseases, 3(2), ofw105. https://doi.org/10.1093/ofid/ofw105
Martinello, Marianne, et al. "Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection." Open forum infectious diseases vol. 3,2 (2016): ofw105. doi: https://doi.org/10.1093/ofid/ofw105
Martinello M, Dore GJ, Skurowski J, Bopage RI, Finlayson R, Baker D, Bloch M, Matthews GV. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infect Dis. 2016 May 18;3(2):ofw105. doi: 10.1093/ofid/ofw105. eCollection 2016 Apr. PMID: 27419177; PMCID: PMC4943543.
Copy Download .nbib Format: NLM
Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.

Hepatology research : the official journal of the Japan Society of Hepatology

Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S.
PMID: 28872737
Hepatol Res. 2018 Feb;48(3):E372-E378. doi: 10.1111/hepr.12977. Epub 2017 Sep 25.

A 40-year-old male patient with virologic relapse after daclatasvir plus asunaprevir therapy for a serogroup 1 hepatitis C virus (HCV) infection visited our hospital for retreatment. Virologic examinations revealed that a genotype 2b HCV strain carrying both NS3-S122N /...

Cite
Kurata H, Uchida Y, Kouyama JI, et al. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2017;48(3):E372-E378doi: 10.1111/hepr.12977.
Kurata, H., Uchida, Y., Kouyama, J. I., Naiki, K., Nakazawa, M., Ando, S., Nakao, M., Motoya, D., Sugawara, K., Inao, M., Imai, Y., Nakayama, N., Tomiya, T., & Mochida, S. (2018). Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatology research : the official journal of the Japan Society of Hepatology, 48(3), E372-E378. https://doi.org/10.1111/hepr.12977
Kurata, Hayato, et al. "Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,3 (2018): E372-E378. doi: https://doi.org/10.1111/hepr.12977
Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2018 Feb;48(3):E372-E378. doi: 10.1111/hepr.12977. Epub 2017 Sep 25. PMID: 28872737.
Copy Download .nbib Format: NLM
Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients.

World journal of hepatology

Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K.
PMID: 28469810
World J Hepatol. 2017 Apr 18;9(11):544-550. doi: 10.4254/wjh.v9.i11.544.

AIM: To survey the efficacy and safety of dual therapy with daclatasvir and asunaprevir in the elderly hepatitis C virus (HCV) patients multicentricity.METHODS: Interferon-ineligible/intolerant patients and non-responders to previous pegylated-interferon/ribavirin therapy with chronic HCV genotype 1b infection were enrolled....

Cite
Tarao K, Tanaka K, Nozaki A, et al. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol. 2017;9(11):544-550doi: 10.4254/wjh.v9.i11.544.
Tarao, K., Tanaka, K., Nozaki, A., Sato, A., Ishii, T., Komatsu, H., Ikeda, T., Komatsu, T., Matsushima, S., & Oshige, K. (2017). Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World journal of hepatology, 9(11), 544-550. https://doi.org/10.4254/wjh.v9.i11.544
Tarao, Kazuo, et al. "Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients." World journal of hepatology vol. 9,11 (2017): 544-550. doi: https://doi.org/10.4254/wjh.v9.i11.544
Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol. 2017 Apr 18;9(11):544-550. doi: 10.4254/wjh.v9.i11.544. PMID: 28469810; PMCID: PMC5395803.
Copy Download .nbib Format: NLM
"Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.

Hepatology research : the official journal of the Japan Society of Hepatology

Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S.
PMID: 28239934
Hepatol Res. 2017 Dec;47(13):1397-1407. doi: 10.1111/hepr.12882. Epub 2017 Apr 19.

AIMS: The therapeutic efficacy of daclatasvir/asunaprevir was inferior in patients with non-structural protein 5A (NS5A)-R30Q mutant hepatitis C virus strains at baseline, compared with those with wild-type strains, even though the half maximal effective concentration of NS5A inhibitors was...

Cite
Uchida Y, Kouyama JI, Naiki K, et al. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017;47(13):1397-1407doi: 10.1111/hepr.12882.
Uchida, Y., Kouyama, J. I., Naiki, K., Sugawara, K., Inao, M., Imai, Y., Nakayama, N., & Mochida, S. (2017). "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatology research : the official journal of the Japan Society of Hepatology, 47(13), 1397-1407. https://doi.org/10.1111/hepr.12882
Uchida, Yoshihito, et al. ""Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,13 (2017): 1397-1407. doi: https://doi.org/10.1111/hepr.12882
Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017 Dec;47(13):1397-1407. doi: 10.1111/hepr.12882. Epub 2017 Apr 19. PMID: 28239934.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 282 entries